Log in

NASDAQ:HZNP - Horizon Therapeutics Stock Price, Forecast & News

$27.53
-0.87 (-3.06 %)
(As of 03/30/2020 09:03 AM ET)
Today's Range
$26.68
Now: $27.53
$28.13
50-Day Range
$24.89
MA: $32.60
$36.83
52-Week Range
$22.69
Now: $27.53
$39.10
Volume1.42 million shs
Average Volume2.05 million shs
Market Capitalization$5.24 billion
P/E Ratio10.16
Dividend YieldN/A
Beta0.86
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company's primary care marketed medicines comprise PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; VIMOVO for the relief of signs and symptoms of OA, RA, and AS and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and MIGERGOT, a therapy to abort or prevent vascular headaches, such as migraines and migraine variants. It has collaboration agreements with Alliance for Lupus Research, Syneos Health, Inc., and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Read More
Horizon Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:HZNP
CUSIP44047T10
Phone011-353-1772-2100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.30 billion
Cash Flow$3.47 per share
Book Value$11.67 per share

Profitability

Net Income$573.02 million

Miscellaneous

Employees1,200
Market Cap$5.24 billion
Next Earnings Date5/13/2020 (Estimated)
OptionableOptionable

Receive HZNP News and Ratings via Email

Sign-up to receive the latest news and ratings for HZNP and its competitors with MarketBeat's FREE daily newsletter.


Horizon Therapeutics (NASDAQ:HZNP) Frequently Asked Questions

How has Horizon Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Horizon Therapeutics' stock was trading at $30.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, HZNP shares have decreased by 9.8% and is now trading at $27.53. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Horizon Therapeutics?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Horizon Therapeutics.

When is Horizon Therapeutics' next earnings date?

Horizon Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Horizon Therapeutics.

How were Horizon Therapeutics' earnings last quarter?

Horizon Therapeutics PLC (NASDAQ:HZNP) issued its earnings results on Wednesday, February, 26th. The biopharmaceutical company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.42 by $0.14. The biopharmaceutical company had revenue of $363.50 million for the quarter, compared to analysts' expectations of $349.25 million. Horizon Therapeutics had a net margin of 44.08% and a return on equity of 23.07%. Horizon Therapeutics's quarterly revenue was up 2.3% compared to the same quarter last year. During the same period last year, the business earned $0.67 EPS. View Horizon Therapeutics' earnings history.

What guidance has Horizon Therapeutics issued on next quarter's earnings?

Horizon Therapeutics issued an update on its FY 2020 Pre-Market earnings guidance on Wednesday, February, 26th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.4-1.42 billion, compared to the consensus revenue estimate of $1.39 billion.

What price target have analysts set for HZNP?

13 equities research analysts have issued 12-month price objectives for Horizon Therapeutics' stock. Their forecasts range from $27.00 to $49.00. On average, they anticipate Horizon Therapeutics' stock price to reach $38.69 in the next twelve months. This suggests a possible upside of 40.5% from the stock's current price. View analysts' price targets for Horizon Therapeutics.

What are Wall Street analysts saying about Horizon Therapeutics stock?

Here are some recent quotes from research analysts about Horizon Therapeutics stock:
  • 1. According to Zacks Investment Research, "Horizon’s efforts to develop its pipeline are impressive. The company's BLA for teprotumumab was accepted by the FDA in September. The FDA set an action date of Mar 8, 2020. A potential approval will significantly boost the company’s performance. The company also initiated the MIRROR study on Krystexxa in the second quarter. The study is designed to support the potential for registration of the drug.  Horizon expects continued strong growth for Krystexxa, going forward, and teprotumumab, beginning 2020. Shares of the company have outperformed the industry in the past year. However, it faces intense competition from pharmaceutical and biotechnology companies and universities. Estimates are stable ahead of Q3 results." (10/29/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We have updated our financial model to include: 1) HZNP’s recent equity offering, and 2) sales for teprotumumab starting in 2020, given the positive Phase 3 results earlier this year. Both the equity raise and positive Phase 3 data support our OW rating on HZNP shares. Therefore, we are raising our PT to $32 from $26. The increase in our PT is driven by upward earnings revisions for 2020+ given we now include risk adjusted sales for teprotumumab in our financial model." (4/2/2019)

Has Horizon Therapeutics been receiving favorable news coverage?

Media stories about HZNP stock have trended somewhat negative recently, InfoTrie reports. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Horizon Therapeutics earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutHorizon Therapeutics.

Who are some of Horizon Therapeutics' key competitors?

What other stocks do shareholders of Horizon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics investors own include Opko Health (OPK), Alibaba Group (BABA), Netflix (NFLX), NVIDIA (NVDA), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Allergan (AGN), Tesla (TSLA), AbbVie (ABBV) and Bank of America (BAC).

Who are Horizon Therapeutics' key executives?

Horizon Therapeutics' management team includes the following people:
  • Mr. Timothy P. Walbert, Chairman, Pres & CEO (Age 52)
  • Mr. Paul W. Hoelscher, Exec. VP & CFO (Age 54)
  • Dr. Shao-Lee Lin M.D., Ph.D., Exec. VP, Head of R&D and Chief Scientific Officer (Age 52)
  • Mr. Barry J. Moze, Exec. VP & Chief Admin. Officer (Age 65)
  • Mr. Robert F. Carey, Exec. VP & Chief Bus. Officer (Age 60)

What is Horizon Therapeutics' stock symbol?

Horizon Therapeutics trades on the NASDAQ under the ticker symbol "HZNP."

Who are Horizon Therapeutics' major shareholders?

Horizon Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (5.39%), William Blair Investment Management LLC (4.73%), FMR LLC (3.49%), Janus Henderson Group PLC (3.14%), Nuveen Asset Management LLC (1.52%) and State Street Corp (1.39%). Company insiders that own Horizon Therapeutics stock include Brian K Beeler, Geoffrey M Curtis, Irina Konstantinovsky, James Samuel Shannon, Jeff Kent, Miles W Mchugh, Paul W Hoelscher, Timothy P Walbert and Vikram Karnani. View institutional ownership trends for Horizon Therapeutics.

Which major investors are selling Horizon Therapeutics stock?

HZNP stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Jennison Associates LLC, Acadian Asset Management LLC, Alyeska Investment Group L.P., Rhenman & Partners Asset Management AB, Russell Investments Group Ltd., Schonfeld Strategic Advisors LLC, and JW Asset Management LLC. Company insiders that have sold Horizon Therapeutics company stock in the last year include Brian K Beeler, Geoffrey M Curtis, Irina Konstantinovsky, James Samuel Shannon, Jeff Kent, Miles W Mchugh, Paul W Hoelscher, Timothy P Walbert, and Vikram Karnani. View insider buying and selling activity for Horizon Therapeutics.

Which major investors are buying Horizon Therapeutics stock?

HZNP stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Norges Bank, Bank of Montreal Can, Renaissance Technologies LLC, Victory Capital Management Inc., Victory Capital Management Inc., William Blair Investment Management LLC, and First Trust Advisors LP. View insider buying and selling activity for Horizon Therapeutics.

How do I buy shares of Horizon Therapeutics?

Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Horizon Therapeutics' stock price today?

One share of HZNP stock can currently be purchased for approximately $27.53.

How big of a company is Horizon Therapeutics?

Horizon Therapeutics has a market capitalization of $5.24 billion and generates $1.30 billion in revenue each year. The biopharmaceutical company earns $573.02 million in net income (profit) each year or $1.94 on an earnings per share basis. Horizon Therapeutics employs 1,200 workers across the globe. View additional information about Horizon Therapeutics.

What is Horizon Therapeutics' official website?

The official website for Horizon Therapeutics is http://www.horizontherapeutics.com/.

How can I contact Horizon Therapeutics?

Horizon Therapeutics' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, DUBLIN L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at 011-353-1772-2100 or via email at [email protected]


MarketBeat Community Rating for Horizon Therapeutics (NASDAQ HZNP)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  822 (Vote Outperform)
Underperform Votes:  418 (Vote Underperform)
Total Votes:  1,240
MarketBeat's community ratings are surveys of what our community members think about Horizon Therapeutics and other stocks. Vote "Outperform" if you believe HZNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HZNP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Featured Article: Hold Rating

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel